Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of brolucizumab for the treatment of neovascular age-related macular degeneration. The systematic review protocol for the current review was established prior to the anticipated issuance of the Healt...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of brolucizumab for the treatment of neovascular age-related macular degeneration. The systematic review protocol for the current review was established prior to the anticipated issuance of the Health Canada Notice of Compliance for brolucizumab, expected on March 12, 2020. The expected recommended dose for brolucizumab is 6 mg (50 μL) administered by intravitreal (IVT) injection every four weeks for the first three doses and every 12 weeks thereafter |
|---|---|
| Physical Description: | 1 PDF file (88 pages) illustrations |